Fresenius Kabi Launches Leucovorin Calcium Injection, USP

January 29, 2019

This injection formulation of USP-grade leucovorin calcium is now available in the United States.

On Jan. 29, 2019, Fresenius Kabi, a health care company specializing in medicines and technologies for infusion, transfusion and clinical nutrition, launched Leucovorin Calcium Injection, USP, for treating toxicity and diminishing the effects of impaired methotrexate elimination. The product, which the company states is the first liquid formulation of leucovorin calcium, is immediately available in the United States.

Leucovorin calcium is also used as a rescue drug after high-dose methotrexate therapy in osteosarcoma, in the treatment of megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible, and in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

The Leucovorin Calcium Injection, USP, product is available in 10 mg/mL single-use vials and in 100 mg/10 mL and 500 mg/50 mL strengths.

“At Fresenius Kabi we are dedicated to finding safe and affordable solutions for health care providers,” said John Ducker, president and CEO of Fresenius Kabi USA, in a company press release. “We are pleased to offer a version of Leucovorin Calcium Injection that eliminates the need for reconstitution, providing pharmacists an efficient way to prepare this medication.”

Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible.

Source: Fresenius Kabi